Sanofi's mRNA Covid-19 vaccine candidate will not be ready this year, says CEO
Paris
A COVID-19 vaccine candidate developed by Sanofi and US group Translate Bio "will not be ready this year", the French drugmaker's chief executive told Le Journal du Dimanche newspaper.
Clinical trials of this vaccine, which will be based on a technology known as mRNA - on which lean approved vaccines of Pfizer/BioNTech and Moderna - are expected to start this quarter.
In December last year, Sanofi had said it was targeting "earliest potential approval" of the shot in the second half of 2021, following positive preclinical data.
"This vaccine will not be ready this year, but it could be of use at a later stage all the more if the fight against variants was to continue," Paul Hudson was quoted as saying. The CEO gave no other details.
The news could mark another blow for Sanofi, already embattled with a delay for another Covid-19 vaccine candidate it hopes to bring to patients and for which the company has teamed up with Britain's GlaxoSmithKline.
GET BT IN YOUR INBOX DAILY
Start and end each day with the latest news stories and analyses delivered straight to your inbox.
The two groups stunned investors last year by warning their traditional, protein-based Covid-19 jab showed an insufficient immune response in older people, delaying its launch towards the end of 2021.
To appease critics, Sanofi said last month it had agreed to fill and pack millions of doses of the Pfizer/BioNTech vaccine from July.
Some 108 million people have been reported to be infected by the novel coronavirus globally and more than 2.4 million have died since first cases were identified in China in December 2019.
Countries worldwide have since the beginning of the year embarked on mass vaccination programmes, with mixed results, and are now confronted with the emergence of several variant strains which forces them to move even more quickly. REUTERS
KEYWORDS IN THIS ARTICLE
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Consumer & Healthcare
Wall Street Journal moves Asia headquarters from Hong Kong to Singapore
South Korea to slap fines on food suppliers for ‘shrinkflation’
Olam outbids Dreyfus’ sweetened deal for Australia’s Namoi, raises offer to A$0.66 per share
Live Nation’s revenue beats estimates as boom in concerts drive ticket sales
Jim Beam owner bets on canned vodka cocktails to double revenue
Cutting the cord?: Events leading up to Cordlife’s MOH suspension and arrests of its directors, ex-group CEO